UP!

ALXN $115.58   View long term graphs

Alexion Pharmaceuticals
Type
Public
Traded as
  • NASDAQ: ALXN
  • NASDAQ-100 component
  • S&P 500 Component
Industry Pharmaceutical
Founded 1992
Founder Leonard Bell
Headquarters New Haven, Connecticut, U.S.
Key people
Leonard Bell (Chairman)
Ludwig N. Hantson (CEO)
Products Soliris
Revenue Increase US$3.03 bil (2017)
Operating income
DecreaseUS$536.67 mil (2015)
Net income
DecreaseUS$144.38 mil (2015)
Total assets IncreaseUS$13.1 bil (2015)
Total equity IncreaseUS$8.26 bil (2015)
Number of employees
3,121(May 2017)
Website www.alxn.com

Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company is also involved in immune system research related to autoimmune diseases. It employs around 2,400 people worldwide. In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, Connecticut, not far from the company's starting point in the same city.

In September 2017, Alexion announced it would be moving its headquarters to Boston, Massachusetts in mid-2018.

Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell. Bell served as the company's CEO until 2015. In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Alexion moved back to New Haven following the completion of New Haven's Downtown Crossing project in December 2015.

Since 2006, Alexion has been a supporter of healthcare research and quality studies at Duke University for aspirin and Clopidogrel (trade name Plavix).

Alexion received U.S. Food and Drug Administration (FDA) approval for Soliris in 2007. It was initially approved to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder. In 2010, there was an outbreak of hemolytic-uremic syndrome caused by Enterohaemorrhagic Escherichia coli (EHEC) in Germany. Soliris was considered a treatment option because of its effectiveness in treating Atypical hemolytic uremic syndrome, an illness similar to the one caused by the EHEC infection.

In April 2011, Alexion was added to the NASDAQ-100, a group composed of the 100 largest non-financial stocks traded on the NASDAQ; with a market value of USD 8.5 billion it replaced Genzyme Corporation.

In April 2015, Bell was replaced as CEO by David Hallal. In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

In December 2016, Alexion's board of directors announced new leadership. David Brennan, a current board member, became interim CEO. David Anderson, formerly the CFO of Honeywell, was appointed CFO, replacing Vikas Sinha. In March 2017, Alexion named Ludwig N. Hantson as its new CEO.

In 2000, Alexion purchased Proliferon Inc., a San Diego, California-based development-stage biopharmaceutical firm, for US$41 million in Alexion stock. Alexion CEO, Leonard Bell, cited Proliferon's ability to produce an "unlimited amount of antibodies" as the reason for the acquisition. At the time Proliferon's annual revenue was about $2.5 million and its assets were valued at $2.1 million. The company has since been renamed Alexion Antibody Technologies Inc.

In December 2011, Alexion acquired Montreal-based Enobia Pharma Corp, the developer of asfotase alpha, a drug used to treat the genetic disorder hypophosphatasia.

In May 2015, Alexion announced plans to purchase the Lexington firm Synageva BioPharma, a maker of rare disease treatments, in a $8.4 billion stock-and-cash deal. The price represented more than a 135% premium over Synageva's market cap at the time. It also represented a valuation of about ten times projected peak sales, double what is typical for the biotech industry.

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

Alexion Pharmaceuticals
(Founded 1992)

Proliferon Inc
(Acq 2000, restructured into Alexion Antibody Technologies Inc)

Enobia Pharma Corp
(Acq 2011)

Synageva BioPharma
(Acq 2015)

As of 2017 Alexion Pharmaceuticals shares are mainly held by institutional investors (Fidelity Investments, T. Rowe Price, BlackRock and others)

Alexion has employed a strategy of developing drugs to combat rare diseases. Since the targeted user base is small for such drugs, clinical drugs tend to be quicker and cheaper than those for mass market drugs. Additionally, big pharmaceutical companies have tended to ignore these markets, creating a niche with minimal competition for Alexion. Insurance companies have generally been willing to pay high prices for such drugs; since few of their customers need the drugs, a high price does not significantly impact the insurance companies' outlays. "The success of specialty drugs for rare diseases comes at a time when the traditional drug business of selling medicines to the masses is in decline...Specialty drugs have gotten more expensive than anyone imagined."

Alexion's first drug, Soliris, first launched in 2007, used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and Paroxysmal nocturnal hemoglobinuria (PNH). It has been approved for use in Canada, the European Union, Japan, and the United States; however, availability in Canada is limited. In Canada, access to the drug is mostly through private clinics; groups such as the Canadian Association of PNH Patients are lobbying to change that. The drug costs roughly $450,000 a year, and is considered the world's most expensive drug. The price of the drug is so high that very few individuals can pay the price. As a result, Alexion hires public relations firms to help families institute campaigns to pressure their governments to pay for the drug. Alexion is putting pressure on to governments to receive their payments from the public purse. The prices charged have a very high margin above the cost price. In addition, much of the research for the development of Soliris originates from publicly funded universities. There is an ethical question as to the pricing of the drug and the ethics of the drug manufacturer. Alexion is well on the way to developing a second very high price and high margined drug.

In September 2011, the FDA officially approved the use of Soliris as a treatment for atypical hemolytic-uremic syndrome in both adults and children. More than half of people with aHUS end up dying of it as a result of damage to vital organs/organ failure (usually involving the kidneys) caused by uncontrolled complement activation. The FDA's decision to grant approval received a positive response from the medical community with the director of Pediatric Nephrology at Atlanta's Children's hospital calling it "the most important advance that has been made for patients and families with this disease".

By 2010 Soliris was considered to be the most expensive drug in the world. It costs £340,200 per year for treatment in the UK and $500,000 a year in Canada. and US$409,500 a year in the United States (2010). In the case of the rarest diseases that afflict fewer than 10,000 people, biotech companies who own the only approved drugs to treat those diseases "can charge pretty much whatever they want." "Before testing Soliris for PNH, Alexion tested the drug for rheumatoid arthritis, which afflicts 1 million Americans. The trials failed. But if it had worked for arthritis, Alexion would likely have had to charge a much lower price for this use, as it would have to compete against drugs that cost a mere $20,000." Alexion started selling Soliris in 2008 making $295 million in 2007 with its stock price rising to 130% in 2010.

In April and May 2013, a controversy arose in Belgium when the media revealed that the government had refused to pay for a seven-year-old boy's treatment because Soliris was too expensive. The boy's medicine cost 9,000 euros every two weeks. On May 4, 2013, De Standaard reported that a press relations (PR) agency working for Alexion had helped the boy's parents communicate their story to the press. It was also reported that the parents had believed their benefactor was a Dutch organization for patients, and that the PR agency acted with permission from Alexion. Several politicians stated that the company was attempting to 'blackmail' the government, charges which Alexion denied. By May 7, 2013 an agreement had been reached to reimburse the medicine.

Pharma, the Belgian pharmaceutical industry's association, opened an internal investigation into the affair, for possible breach of the association's ethical standards by Alexion. However, on June 12, Alexion received a court gag order against Pharma, preventing it from communicating its investigation. At the same time, Pharma opened a court case against Alexion Pharma Belgium. The gag order was revoked by the end of September 2013, but the case was still pending in March 2015.

In October 2017 the FDA approved the use of Soliris to treat adult patients with generalized myasthenia gravis (gMG). In November 2017 the company received a patent for Soliris from the Japanese Patent Office.

In October 2015, Alexion's second drug, Strensiq (asfotase alfa), was approved by the US FDA. It is used to treat hypophosphatasia, a rare metabolic disorder.

Kanuma, which Alexion acquired in its acquisition of Synageva, was approved in 2015 to treat lysosomal acid lipase deficiency, a fatal genetic disorder that cause fatty material to build up in blood vessel walls, the liver, and other tissues. Alexion estimates that the drug could eventually have annual sales of more than $1 billion.

In 2013, 36% Alexion's sales originated in the US, down from 37% the previous year; 33% came from Europe, down from 35%; Japan accounted for just over 10%. Revenue was impacted by higher unit volumes for Soliris (up 40%), and a decreased average price related to rebates in Europe. Acquisition related costs fell significantly from $22 million to just $5 million. R&D spending reached a record high of $317 million in 2013 up 83% from the previous year.

When Soliris was first approved, peak annual sales were estimated at $150 million. However, by September 2013 quarterly sales of Soliris topped $400 million. Sales during the first quarter of 2015 were just over US$600 million, and are still on the rise.

Before the Synageva purchase announcement, Alexion was valued at $34 billion. The stock is up roughly 800% in the last five years and is currently trading at 46 times estimated earnings. Due to the niche nature of its market and the high cost of Soliris, the company has enjoyed a high profit margin.

News

Alexion Pharmaceuticals, Inc. 6.31% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-01-28 Future report Set alerts
Q3 2020 2020-10-21 Future report Set alerts
Q2 2020 2020-07-30 3.11 -4.84
Q1 2020 2020-05-06 3.22 2.50
Q4 2019 2020-01-30 2.71 4.00
Q3 2019 2019-10-23 2.79 2.08
Q2 2019 2019-07-24 2.64 2.04
Q1 2019 2019-04-25 2.39 2.61
Q4 2018 2019-02-04 2.14 -0.20
Q3 2018 2018-10-24 2.02 1.47

Ratings

2016-07-13 Lower Price Target SunTrust Banks Inc. Buy $220.00 to $197.00
2016-07-12 Initiated Coverage Royal Bank Of Canada Outperform $188.00
2016-07-11 Upgrade Credit Suisse Group AG Neutral to Outperform $186.00 to $165.00
2016-07-08 Reiterated Rating Leerink Swann Buy $200.00
2016-07-07 Reiterated Rating Piper Jaffray Cos. Buy
2016-06-29 Reiterated Rating Morgan Stanley Overweight
2016-06-29 Reiterated Rating Cowen and Company Buy
2016-06-27 Upgrade Citigroup Inc. Neutral to Buy $154.00
2016-06-26 Reiterated Rating Piper Jaffray Buy
2016-06-26 Reiterated Rating Piper Jaffray Cos. Buy
2016-06-17 Reiterated Rating Leerink Swann Buy
2016-06-13 Reiterated Rating Robert W. Baird Neutral $145.00
2016-06-08 Reiterated Rating Cowen and Company Buy
2016-06-07 Lower Price Target Barclays Equal Weight $180.00 to $165.00
2016-06-07 Reiterated Rating Citigroup Inc. Hold
2016-06-07 Reiterated Rating Leerink Swann Buy
2016-06-07 Reiterated Rating Oppenheimer Buy $228.00 to $221.00
2016-06-07 Reiterated Rating Brean Capital Buy
2016-06-07 Reiterated Rating BMO Capital Markets Buy $168.00 to $160.00
2016-06-07 Reiterated Rating Morgan Stanley Overweight $203.00 to $189.00
2016-06-07 Lower Price Target Barclays PLC Equal Weight $180.00 to $165.00
2016-06-07 Reiterated Rating Oppenheimer Holdings Inc. Buy $228.00 to $221.00
2016-06-06 Reiterated Rating Piper Jaffray Buy $212.00
2016-06-06 Reiterated Rating Credit Suisse Hold $195.00 to $186.00
2016-06-06 Reiterated Rating Bank of America Buy
2016-06-06 Reiterated Rating Credit Suisse Group AG Hold $195.00 to $186.00
2016-06-06 Reiterated Rating Bank of America Corp. Buy
2016-05-31 Reiterated Rating Oppenheimer Outperform $228.00
2016-05-29 Reiterated Rating Jefferies Group Hold
2016-05-12 Reiterated Rating Leerink Swann Buy $200.00 to $210.00
2016-05-09 Boost Price Target Barclays Equal Weight $175.00 to $180.00
2016-04-30 Reiterated Rating Morgan Stanley Buy
2016-04-30 Downgrade BMO Capital Markets Buy
2016-04-30 Reiterated Rating Leerink Swann Buy
2016-04-29 Upgrade BMO Capital Markets Market Perform to Outperform $168.00
2016-04-28 Reiterated Rating Cowen and Company Buy
2016-04-28 Reiterated Rating Brean Capital Buy
2016-04-28 Reiterated Rating Piper Jaffray Buy
2016-04-26 Reiterated Rating Oppenheimer Outperform $228.00
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-04-10 Reiterated Rating Leerink Swann Outperform
2016-04-08 Boost Price Target Morgan Stanley $195.00 to $210.00
2016-04-06 Initiated Coverage BMO Capital Markets Market Perform $165.00
2016-04-05 Reiterated Rating Piper Jaffray Buy $212.00
2016-04-01 Reiterated Rating Morgan Stanley Buy $195.00
2016-03-19 Reiterated Rating Leerink Swann Buy $217.00 to $216.00
2016-03-07 Reiterated Rating Cowen and Company Buy $216.00
2016-03-07 Downgrade Robert W. Baird Outperform to Neutral $221.00 to $170.00
2016-02-25 Initiated Coverage Citigroup Inc. Neutral $165.00
2016-02-22 Lower Price Target Goldman Sachs $186.00 to $168.00
2016-02-22 Lower Price Target Goldman Sachs Group Inc. $186.00 to $168.00
2016-02-08 Reiterated Rating Jefferies Hold $190.00 to $165.00
2016-02-08 Reiterated Rating Jefferies Group Hold $190.00 to $165.00
2016-02-06 Reiterated Rating Leerink Swann Outperform $217.00
2016-02-05 Reiterated Rating Bank of America Buy $227.00 to $204.00
2016-02-04 Lower Price Target Stifel Nicolaus Buy $245.00 to $230.00
2016-02-04 Lower Price Target JPMorgan Chase & Co. $225.00 to $185.00
2016-02-04 Lower Price Target Jefferies Group Hold $190.00 to $165.00
2016-02-04 Lower Price Target Goldman Sachs Neutral $199.00 to $186.00
2016-02-04 Reiterated Rating Brean Capital Buy $221.00
2016-02-04 Reiterated Rating Piper Jaffray Overweight $212.00
2016-02-04 Lower Price Target Barclays Equal Weight $202.00 to $175.00
2016-01-19 Initiated Coverage Credit Suisse Neutral $201.00
2016-01-07 Downgrade BTIG Research Buy to Neutral
2016-01-06 Initiated Coverage SunTrust Buy $225.00
2016-01-06 Initiated Coverage SunTrust Banks Inc. Buy $225.00
2016-01-04 Reiterated Rating Piper Jaffray Buy $221.00
2015-12-11 Reiterated Rating Piper Jaffray Overweight $221.00
2015-12-11 Reiterated Rating Brean Capital Buy $221.00
2015-12-11 Lower Price Target Stifel Nicolaus Buy $250.00 to $245.00
2015-12-09 Reiterated Rating Oppenheimer Outperform $228.00
2015-11-03 Reiterated Rating Cowen and Company Outperform $216.00
2015-11-01 Reiterated Rating Piper Jaffray Overweight $221.00
2015-10-28 Reiterated Rating Robert W. Baird Outperform $221.00
2015-10-27 Lower Price Target Barclays Equal Weight $205.00 to $202.00
2015-10-26 Reiterated Rating Piper Jaffray Buy $235.00
2015-10-26 Reiterated Rating Brean Capital Buy
2015-10-26 Reiterated Rating Oppenheimer Buy $228.00
2015-10-15 Reiterated Rating Barclays Equal Weight
2015-10-13 Reiterated Rating Cowen and Company Outperform $216.00
2015-10-13 Reiterated Rating Raymond James Strong-Buy $225.00
2015-10-13 Reiterated Rating Raymond James Financial Inc. Strong-Buy $225.00
2015-10-02 Upgrade Morgan Stanley Equal Weight to Overweight $186.00 to $211.00
2015-09-24 Reiterated Rating Oppenheimer Buy $228.00
2015-09-14 Downgrade Barclays Overweight to Equal Weight $220.00 to $205.00
2015-09-04 Reiterated Rating Brean Capital Buy $221.00
2015-08-31 Initiated Coverage Raymond James Strong-Buy $225.00
2015-08-04 Reiterated Rating Deutsche Bank Buy $215.00
2015-08-04 Reiterated Rating Deutsche Bank AG Buy $215.00
2015-07-31 Boost Price Target Stifel Nicolaus Buy $239.00 to $257.00
2015-07-31 Reiterated Rating Brean Capital Buy $213.00 to $221.00
2015-07-27 Initiated Coverage JPMorgan Chase & Co. Overweight $249.00
2015-07-23 Reiterated Rating Piper Jaffray Buy $235.00
2015-07-20 Boost Price Target Goldman Sachs Neutral $200.00 to $202.00
2015-07-02 Reiterated Rating Barclays Overweight $205.00
2015-06-23 Set Price Target Sanford C. Bernstein Buy $267.00
2015-06-18 Reiterated Rating Leerink Swann Outperform $224.00
2015-05-18 Reiterated Rating Morgan Stanley Equal Weight $185.00 to $177.00
2015-05-10 Reiterated Rating Morgan Stanley Neutral $185.00 to $177.00
2015-05-10 Reiterated Rating Barclays Overweight $225.00 to $205.00
2015-05-10 Reiterated Rating SunTrust Buy $236.00 to $246.00
2015-05-07 Set Price Target Citigroup Inc. Hold $208.00 to $173.00
2015-05-07 Upgrade Nomura Neutral to Buy $222.00 to $246.00
2015-05-07 Lower Price Target Brean Capital Buy $215.00 to $213.00
2015-05-07 Upgrade Nomura Holdings Inc. Neutral to Buy $222.00 to $246.00
2015-05-06 Reiterated Rating Piper Jaffray Overweight $214.00
2015-04-27 Initiated Coverage Oppenheimer Outperform
2015-04-26 Reiterated Rating Brean Capital Buy $215.00
2015-04-26 Reiterated Rating Piper Jaffray Outperform $214.00
2015-04-24 Lower Price Target Nomura Neutral $223.00 to $222.00
2015-04-24 Boost Price Target Jefferies Group Hold $164.00 to $167.00
2015-03-19 Reiterated Rating BTIG Research Buy $250.00
2015-01-30 Reiterated Rating Citigroup Inc. Hold $199.00 to $208.00
2015-01-30 Boost Price Target Jefferies Group Hold $161.00 to $164.00
2015-01-30 Boost Price Target Leerink Swann Outperform $200.00 to $224.00
2015-01-30 Boost Price Target Stifel Nicolaus Buy $230.00 to $236.00
2015-01-08 Reiterated Rating Brean Capital Buy $215.00
2015-01-08 Reiterated Rating Piper Jaffray Overweight $214.00
2015-01-08 Lower Price Target Jefferies Group Hold $170.00 to $161.00
2015-01-06 Initiated Coverage Barclays Overweight $225.00
2015-01-05 Initiated Coverage BTIG Research Buy $250.00
2015-01-05 Downgrade Morgan Stanley Overweight to Equal Weight $202.00
2015-01-05 Downgrade Nomura Buy to Neutral $224.00 to $223.00
2014-11-07 Reiterated Rating JPMorgan Chase & Co. Overweight $220.00 to $225.00
2014-10-01 Initiated Coverage Bank of America Buy $197.00
2014-09-04 Initiated Coverage SunTrust Buy $229.00
2014-09-04 Initiated Coverage Credit Suisse Neutral
2014-07-25 Reiterated Rating Nomura Buy $222.00 to $224.00
2014-07-25 Reiterated Rating Stifel Nicolaus Buy $220.00 to $222.00
2014-07-25 Reiterated Rating JPMorgan Chase & Co. Overweight $210.00 to $220.00
2014-07-25 Reiterated Rating Credit Suisse Neutral $174.00 to $179.00
2014-05-09 Reiterated Rating JPMorgan Chase & Co. Overweight $200.00 to $210.00
2014-04-25 Reiterated Stifel Buy $219 to $220
2014-04-25 Reiterated Rating Stifel Nicolaus Buy $219.00 to $220.00
2014-04-21 Upgrade Ned Davis Research Sell to Neutral
2014-03-27 Boost Price Target Credit Suisse Neutral $171.00
2014-03-11 Reiterated UBS Buy $185 to $202
2014-03-11 Reiterated Stifel Buy $207 to $219
2014-03-11 Boost Price Target Robert W. Baird $175.00 to $199.00
2014-03-11 Boost Price Target Brean Capital $200.00 to $215.00
2014-03-11 Boost Price Target Nomura $214.00 to $222.00
2014-03-11 Boost Price Target Stifel Nicolaus Buy $207.00 to $219.00
2014-03-06 Boost Price Target Barclays Outperform $181.00 to $193.00
2014-02-10 Boost Price Target Deutsche Bank Buy $125.00 to $205.00
2014-01-31 Reiterated Stifel Buy $138 to $207
2014-01-31 Boost Price Target Canaccord Genuity Buy $161.00 to $200.00
2014-01-31 Boost Price Target Barclays Overweight $141.00 to $181.00
2014-01-31 Boost Price Target Jefferies Group Hold $106.00 to $145.00
2014-01-31 Boost Price Target Leerink Swann $125.00 to $200.00
2014-01-31 Boost Price Target Stifel Nicolaus Buy $138.00 to $207.00
2014-01-30 Boost Price Target Brean Capital Buy $142.00 to $200.00
2014-01-10 Reiterated Rating Barclays Overweight $127.00 to $141.00
2014-01-08 Initiated Coverage Nomura Buy $150.00
2014-01-06 Reiterated UBS Buy $130 to $150
2014-01-06 Boost Price Target Canaccord Genuity Buy $138.00 to $161.00
2014-01-06 Downgrade Goldman Sachs Buy to Neutral
2013-11-26 Initiated Coverage Piper Jaffray Overweight $172.00
2013-10-25 Reiterated Stifel Buy $131 to $138
2013-10-25 Boost Price Target Barclays Overweight $121.00 to $127.00
2013-10-25 Boost Price Target Oppenheimer $115.00 to $125.00
2013-10-25 Boost Price Target Jefferies Group Hold $97.00 to $106.00
2013-10-25 Boost Price Target Guggenheim Buy $127.00 to $130.00
2013-10-25 Boost Price Target Cowen and Company Outperform $115.00 to $123.00
2013-10-25 Boost Price Target Canaccord Genuity Buy $132.00 to $138.00
2013-10-25 Boost Price Target Stifel Nicolaus Buy $131.00 to $138.00
2013-09-18 Boost Price Target Goldman Sachs Hold $122.00 to $139.00
2013-07-26 Reiterated Barclays Overweight $118 to $121
2013-04-26 Reiterated UBS Buy $120 to $123
2012-09-24 Reiterated Canaccord Genuity Buy $115 to $132
2012-04-25 Reiterated Canaccord Genuity Buy $95 to $100
2012-04-25 Reiterated Barclays Overweight $84 to $104
2012-03-26 Initiated Canaccord Genuity Buy $95
2012-02-23 Upgrade UBS Neutral to Buy $73 to $99
2016-07-13 Lower Price Target SunTrust Banks Inc. Buy $220.00 to $197.00
2016-07-12 Initiated Coverage Royal Bank Of Canada Outperform $188.00
2016-07-11 Upgrade Credit Suisse Group AG Neutral to Outperform $186.00 to $165.00
2016-07-08 Reiterated Rating Leerink Swann Buy $200.00
2016-07-07 Reiterated Rating Piper Jaffray Cos. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
BAKER BROS. ADVISORS LP 3.70%  (7317906) ACAD / ALXN / AQXP / BCRX / GHDX / IDRA / INCY / MRTX / SGEN / XOMA /
BAKER FELIX 3.09%  (6103727) ACAD / ALXN / BCRX / GEVA / GHDX / MRTX / SGEN /
BELL LEONARD CEO 0.20%  (390670) ALXN /
Hallal David EVP, Chief Commercial Officer 0.10%  (189266) ALXN /
MADRI JOSEPH A 0.09%  (179217) ALXN /
Sinha Vikas EVP & CFO 0.09%  (178463) ALXN /
HANTSON LUDWIG CEO 0.08%  (153940) ALXN / BAX /
SQUINTO STEPHEN P EVP, Chief Global Ops. Officer 0.05%  (106508) ALXN / BOLD /
Clancy Paul J EVP, Chief Financial Officer 0.05%  (98550) AGIO / ALXN / BIIB / INCY /
Moriarty John B SVP & General Counsel 0.04%  (74537) ALXN / PTLA /
LINK MAX 0.03%  (59469) ALXN / AMDA / BSTC / CLSN / CYTR / DSCO /
O'Neill Julie EVP. Global Operations 0.03%  (51727) ALXN /
MACKAY MARTIN EVP & Global Head of R&D 0.03%  (50688) ALXN / CRL /
Wagner Heidi L SVP, Global Government Affairs 0.02%  (49140) ALXN /
Islam Saqib SVP, Chief Strat & Port. Off. 0.02%  (43799) ALXN /
Carmichael Clare SVP, Chief HR Officer 0.02%  (39161) ALXN /
Goff Brian EVP & Chief Commercial Officer 0.02%  (37902) ALXN /
ORLOFF JOHN J EVP, Research & Development 0.02%  (33905) ALXN / QLTI /
Thiel Carsten SVP, EMEA & Asia Pacific 0.02%  (33860) ALXN / PTBI /
Franchini Indrani Lall EVP, Chief Compliance Officer 0.02%  (33375) ALXN /
LAW ANNE-MARIE EVP and CHRO 0.02%  (31312) ALXN / H /
MATHIS LARRY 0.02%  (30351) ALXN / HTA /
COUGHLIN CHRISTOPHER J 0.01%  (26333) ALXN / COV / DNB / DPRX / FRX / HOLX /
Wright Frank J SVP, President Alxn Pharm Intl 0.01%  (19670) ALXN / PRSC /
Miller Edward SVP, Chief Compliance Officer 0.01%  (19284) ALXN /
Rummelt Andreas 0.01%  (17246) ALXN /

Comments